Actinium Pharmaceuticals, Inc. (ATNM) is “One to Watch”

Actinium Pharmaceuticals is a biopharmaceutical company with a proprietary platform that combines the precision targeting of monoclonal antibodies with the killing power of alpha and beta radioisotopes, the former being the most potent cancer killing agents in existence. Leveraging this platform and its ties with leading cancer institutions such as Sloan-Kettering (its largest shareholder), MD Anderson, Fred Hutchison, and Johns Hopkins, the company is focused on developing drugs for underserved cancers with no approved drugs which have multi-billion dollar market potential.

Iomab-B, Actinium’s lead product candidate, targets age 55+ patients who suffer from one of the deadliest of blood cancers called Acute Myeloid Leukemia (AML). There are no approved drugs for AML patients and most die within six months. For the few that do manage to go into remission, a bone marrow transplant offers a chance at being cured. However, even this is a risky procedure for these patients and most do not survive beyond six months. But in a Phase 2 trial, one in five patients who received Iomab-B before a bone marrow transplant made it past the two year anniversary when they are considered cured versus almost zero for those who do not. These results imply such a medical breakthrough that the FDA has agreed that the company may conduct just one pivotal trial before filing for BLA approval, assuming it is successful. The primary endpoint in the pivotal Phase 3 trial is durable complete remission, defined as a complete remission lasting 6 months. The Phase 1/2 trial results showed that sixty percent of older patients with advanced refractory and relapsed leukemia achieved disease fee survival after six months.

Iomab-B has shown in many cancers during several Phase 1 and 2 trials with over 300 patients that its use can meaningfully increase survival of bone marrow transplant patients, and the company is initially developing it for AML because it is the fastest path to market. The leading experts in the transplant community recognize that Iomab-B has the potential to meaningfully increase the success rate of bone marrow transplants and offer patients who are condemned to die a chance of being cured. As bone marrow transplants are already the fastest growing hospital procedure and a multi-billion dollar market despite their high failure rate, this bodes well for Iomab-B. Also, bone marrow transplants are delivered in under two hundred centers in the U.S. with most transplants being done in just twenty centers. This implies Actinium can commercialize Iomab-B on its own in the US without a major salesforce; especially as it has the support of leading experts and there are no approved drugs for this purpose.

However, Actinium is no one trick pony. It has another drug called Actimb-A for first line treatment of AML in a Phase 1/2 trial. Over time, the biggest market potential for Actinium lies in the fact that its highly patented platform technology could be used to target a wide variety of cancers. Preclinical and clinical work has already focused on Non-Hodgkin Lymphoma (NHL), brain cancer, bladder cancer, ovarian cancer, breast cancer, prostate cancer, and a number of other cancer related indications. Aside from Iomab-B, the company plans to develop its products through Phase II clinical trials and then partner with an appropriate third party to complete development and commercialization. The compelling advantages of the Actinium’s platform should continue to draw attention from the healthcare and investor communities. A closer look at their technology will further illustrate the immense licensing and acquisition potential inherent in the company’s high-momentum product pipeline. In fact its closest technology competitor, Algeta, which is about 3-4 years ahead from a market perspective, was just acquired by Bayer for $2.9 billion.

Key Investment Highlights

• Breakthrough Therapy Potential in Multiple Billion Dollar Markets

• Expert Team with the Vision and Ability to Materialize Full Potential

• Proprietary Platform Poised to Deliver Blockbuster Cancer Drugs

• Treated over 300 patients in Multiple Phase 1 and Phase II Clinical Trials

For more information, visit www.actiniumpharmaceuticals.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html